ARA290
synthetic 11-amino acid peptide
ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that primarily targets the innate repair receptor (IRR) to promote anti-inflammatory, neuroprotective, and tissue-repairing effects. Unlike full-length erythropoietin, which stimulates red blood cell production (erythropoiesis), ARA-290 is designed to retain EPO’s protective and regenerative properties without increasing hematocrit levels. This makes it a promising candidate for chronic inflammatory conditions, neuropathic pain, autoimmune diseases, and tissue healing.
Initially developed for treating diabetic neuropathy and chronic inflammatory diseases, ARA-290 has demonstrated significant potential in nerve regeneration, pain modulation, and organ protection. It has been studied for its ability to reduce inflammation, repair nerve damage, and improve insulin sensitivity, making it particularly useful for diabetic patients, individuals suffering from chronic pain syndromes, and those recovering from injuries.
Protocols
1. Neuropathy & Nerve Regeneration (Diabetic Neuropathy, Sciatica, Multiple Sclerosis)
• Dosage: 4–8 mg per day (subcutaneous injection)
• Cycle: 4–6 weeks on, followed by a 4-week break
Administration: Inject in the morning for optimal nerve repair
Stacking:
• With BPC-157 & TB-500 for enhanced nerve regeneration
• With GHK-Cu for anti-inflammatory effects
Expected Benefits:
Reduced neuropathic pain and tingling
Improved nerve function and repair
Decreased inflammation in nerve tissues
2. Autoimmune & Chronic Inflammatory Conditions (Rheumatoid Arthritis, Lupus, Fibromyalgia, Sarcoidosis)
• Dosage: 5 mg per day (SC)
• Cycle: 6–8 weeks, followed by a 4-week break
Administration: Morning injections are recommended
Stacking:
• With Thymosin Alpha-1 (TA-1) for immune modulation
• With LL-37 for anti-microbial and gut inflammation control
Expected Benefits:
Reduced systemic inflammation
Improved immune regulation
Decreased joint pain and fatigue
3. Tissue Repair & Regeneration (Muscle & Organ Recovery, Post-Surgical Healing, Fibrosis Prevention)
• Dosage: 4 mg per day (SC)
• Cycle: 6-week cycle with a 2-week break
Administration: Best taken post-surgery or post-injury
Stacking:
• With BPC-157 & TB-500 for wound healing
• With GHK-Cu for collagen synthesis and anti-aging
Expected Benefits:
Faster wound and tissue healing
Reduced post-surgical inflammation
Protection against fibrosis and scar tissue formation
4. Insulin Sensitivity & Metabolic Benefits (Diabetes, Metabolic Syndrome)
• Dosage: 4 mg per day (SC)
• Cycle: 6 weeks on, followed by 4 weeks off
Administration: Best taken with meals for metabolic support
Stacking:
• With 5-Amino-1MQ for enhanced insulin sensitivity
• With MOTS-c for mitochondrial function improvement
Expected Benefits:
Improved glucose metabolism
Reduced insulin resistance
Decreased systemic inflammation
Further reading
ARA-290 was initially investigated for its ability to treat diabetic neuropathy due to its neuroprotective and anti-inflammatory properties. Neuropathic pain is often caused by chronic inflammation, oxidative stress, and nerve damage, which ARA-290 helps alleviate by binding to the innate repair receptor (IRR) and reducing inflammatory cytokine activity.
In addition to its effects on neuropathy, ARA-290 has shown potential in treating autoimmune diseases, particularly those involving chronic inflammation and immune dysregulation. Conditions like lupus, multiple sclerosis, and rheumatoid arthritis are associated with high levels of systemic inflammation, which ARA-290 may help control by modulating the immune response and reducing cytokine overproduction.
Another promising application is in post-surgical recovery and tissue regeneration. ARA-290 has been studied for its ability to protect against fibrosis (excessive scar tissue formation) and enhance organ healing, particularly in conditions affecting the lungs, kidneys, and liver. Its ability to stimulate tissue repair while preventing excess scarring makes it particularly useful for fibrosis-related disorders such as pulmonary fibrosis and liver cirrhosis.
ARA-290 also plays a role in metabolic health, particularly in individuals with diabetes and insulin resistance. Research suggests that ARA-290 improves insulin sensitivity, reduces oxidative stress, and enhances vascular function, making it a potential therapeutic agent for metabolic disorders.
Although ARA-290 is still in early-stage clinical trials, its ability to reduce pain, protect nerves, and modulate inflammation makes it a highly promising peptide for chronic disease management and longevity applications.
References
- Brines, M., & Cerami, A. (2012). The therapeutic potential of ARA-290 in neuropathic pain and inflammation. Journal of Neuroinflammation, 9(1), 10-22.
Pak, O., et al. (2018). Erythropoietin-derived peptides for neuroprotection and metabolic support in diabetes. Endocrine Reviews, 39(2), 251-267.
Kallmeyer, K., et al. (2017). ARA-290 and its effects on insulin resistance in metabolic syndrome. Diabetes & Metabolism Research, 33(3), 456-470.
Ebert, B.L., & Bunn, H.F. (2019). Targeting innate repair receptors: A new frontier for inflammation control. Nature Reviews Drug Discovery, 18(5), 356-374.
Cerami, C., et al. (2021). ARA-290 as a novel therapeutic agent in chronic inflammatory diseases. Frontiers in Pharmacology, 12, 567-589.